Multimodal Movement Tracking in CIDP
Official title: Prospective Observational Cohort Study to Quantitatively Characterize Movement Patterns and Their Longitudinal Trajectories in Chronic Inflammatory Demyelinating Polyneuropathy Using an Xsens Inertial Measurement Suit and Smartwatch Sensors
Run by Heinrich-Heine University, Duesseldorf · NCT07882797 · Data updated 2026-11-12
This study tests whether high-resolution whole-body motion data from wearable sensors can reveal changes in motor function for adults with CIDP undergoing treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Heinrich-Heine University, Duesseldorf Academic / other |
| Locations | 1 site (Düsseldorf, North Rhine-Westphalia) |
| Status | Recruiting |
| Started | October 23, 2026 |
| Main results expected | January 1, 2028 |
| Study ends | January 1, 2028 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT07882797 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with CIDP who can safely perform the standardized movement protocol and provide informed consent.
✕Probably not a fit
Patients with CIDP who have confounding conditions or orthopedic issues that substantially affect movement may not benefit from the sensor-based assessments.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, longitudinal observational study uses a wearable motion-sensing system (Xsens) to collect three-dimensional kinematic data from CIDP patients during a standardized movement protocol. Researchers will compare sensor-derived movement measures with traditional clinical scores, strength tests, and patient-reported outcomes to see how well they track functional status over time. Exploratory analyses will investigate whether changes in movement patterns reflect changes in everyday function and whether distinct movement phenotypes exist among participants. Blood samples will be collected as part of ancillary analyses to support the characterization of motor impairment. The study aims to identify objective, multidimensional biomarkers of motor function that may complement current clinical assessments in CIDP.
Why it matters
Potential benefit: If successful, the approach could provide objective, continuous measures of motor function that complement existing assessments and help tailor treatment for CIDP patients.
How similar studies have gone: Previous work in other motor disorders suggests that high-resolution motion data can reveal functional changes not captured by standard scales, though CIDP-specific evidence is emerging.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) according to current EAN/PNS diagnostic criteria * Age ≥18 years * Ability to understand and perform the standardized movement protocol safely * Written informed consent prior to study participation Exclusion Criteria: * Additional neurological diseases that substantially affect motor function as evaluated by the principal investigator * Relevant orthopedic or rheumatological conditions that substantially influence movement performance as determined by the principal investigator
Where it's running
-
University Hospital Düsseldorf
Düsseldorf, North Rhine-Westphalia, Germany Recruiting
Study contacts
- Study coordinator: Dr. med. Lars Masanneck
- Email: neuro-trials@med.uni-duesseldorf.de
- Phone: 0049 211 8117887
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using a smartwatch to monitor subcutaneous immunoglobulin treatment in CIDP
This project will test whether smartwatch data like step counts and activity levels can show disease severity and treatment response in adults with CIDP who are switching from IVIG to subcutaneous immunoglobulin (fSCIG).
-
Empasiprubart versus IVIg for treating CIDP in adults
This trial tests whether empasiprubart works as well as IVIg and is safe for adults with CIDP who currently benefit from IVIg.
-
Safety assessment of efgartigimod exposure during pregnancy and breastfeeding
This study is trying to see if efgartigimod is safe for pregnant women and breastfeeding mothers, and how it affects their babies.
-
Comparing subcutaneous and intravenous immunoglobulin treatments for CIDP
This study is testing whether a new way of giving immunoglobulin treatment under the skin works better than the traditional method through an IV for people with Chronic Inflammatory Demyelinating Polyneuropathy who haven't been treated before.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.